DDInter1040 DDInter1658
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Letrozole {u} (Compound) resembles {v} (Compound) Bifonazole
Letrozole {u} (Compound) treats {v} (Disease) breast cancer
Letrozole {u} (Compound) binds {v} (Gene) CYP19A1
Letrozole {u} (Compound) upregulates {v} (Gene) KIAA0355
Letrozole {u} (Compound) downregulates {v} (Gene) ACAT2
Letrozole {u} (Compound) causes {v} (Side Effect) Mucosal dryness
Letrozole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Letrozole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenobarbital
Letrozole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Estrone sulfate
Letrozole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conivaptan
Letrozole (Compound) resembles Bifonazole (Compound)
Letrozole (Compound) treats breast cancer (Disease)
Letrozole (Compound) binds CYP19A1 (Gene)
Letrozole (Compound) upregulates KIAA0355 (Gene)
Letrozole (Compound) downregulates ACAT2 (Gene)
Letrozole (Compound) causes Mucosal dryness (Side Effect)
Letrozole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Letrozole may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan